Press CrystalGenomics and Standigm, Agree to Collaborate on Utilizing Artificial Intelligence and Structure-Based Drug Design Technologies in Drug R&D
Seoul, Korea, South, June 01, 2017 –(PR.com)– CrystalGenomics, Inc. (KOSDAQ: 083790) and Standigm, Inc., today announced the collaborative partnership to apply Artificial Intelligence (AI) to the research and development of novel drugs.
News Standigm and CrystalGenomics announce partnership to discover novel therapeutics in cancer, rheumatoid arthritis and liver related diseases.
Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multiple therapeutic areas including cancer, rheumatoid arthritis and liver related diseases.
Date : January 23-25, 2017
Location : Silicon Valley, CA, USAJinhan Kim, Standigm CEO, spoke about StandigmAI, the drug repositioning solution, in the Precision Medicine World Conference (PMWC) Silicon Valley.
Standigm, Inc. today announced that it has raised $3 million (3.4 billion won) in seed funding from three capital firms: K-Cube Ventures LLC, LB Investment, Inc., and Autism Investment Co., Ltd.